Jefferies Financial Group Initiates Coverage on ICU Medical (NASDAQ:ICUI)

Jefferies Financial Group began coverage on shares of ICU Medical (NASDAQ:ICUI) in a report released on Monday, Marketbeat reports. The brokerage issued a hold rating and a $183.00 price target on the medical instruments supplier’s stock.

A number of other research firms have also recently commented on ICUI. Raymond James upped their target price on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research note on Thursday, October 10th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Finally, KeyCorp increased their price objective on ICU Medical from $136.00 to $147.00 and gave the stock an “overweight” rating in a research note on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, ICU Medical has a consensus rating of “Moderate Buy” and an average target price of $170.25.

ICU Medical Trading Down 1.8 %

Shares of NASDAQ ICUI opened at $180.51 on Monday. The business’s 50 day moving average is $169.53 and its two-hundred day moving average is $131.54. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 1.08. ICU Medical has a 1-year low of $78.28 and a 1-year high of $188.53. The stock has a market capitalization of $4.40 billion, a P/E ratio of -73.68 and a beta of 0.66.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The company had revenue of $596.50 million for the quarter, compared to analysts’ expectations of $556.64 million. During the same period in the previous year, the firm posted $1.58 earnings per share. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. As a group, research analysts expect that ICU Medical will post 3.76 EPS for the current year.

Insiders Place Their Bets

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares in the company, valued at $18,665,666.78. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares in the company, valued at approximately $18,665,666.78. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel Woolson sold 2,502 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the sale, the vice president now owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,552 shares of company stock worth $6,679,322 over the last 90 days. Company insiders own 6.70% of the company’s stock.

Institutional Trading of ICU Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in ICU Medical by 14.8% during the 4th quarter. Vanguard Group Inc. now owns 2,440,729 shares of the medical instruments supplier’s stock worth $243,438,000 after purchasing an additional 315,103 shares during the period. Silvercrest Asset Management Group LLC grew its position in shares of ICU Medical by 109.4% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock valued at $29,882,000 after acquiring an additional 145,485 shares during the period. Mesirow Institutional Investment Management Inc. acquired a new stake in shares of ICU Medical during the 1st quarter valued at about $15,425,000. Victory Capital Management Inc. grew its position in shares of ICU Medical by 2,966.3% during the 2nd quarter. Victory Capital Management Inc. now owns 141,848 shares of the medical instruments supplier’s stock valued at $16,844,000 after acquiring an additional 137,222 shares during the period. Finally, Millennium Management LLC lifted its stake in ICU Medical by 327.8% in the 2nd quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier’s stock valued at $16,158,000 after buying an additional 104,264 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.